VERXVertex
About Vertex
Vertex (NASDAQ:VERX) specializes in creating transformative medicines for people with serious diseases, with a focus on treating cystic fibrosis (CF). Beyond CF, Vertex is actively exploring treatments in other serious diseases through a pipeline of research and development projects. The company’s objective is to develop and commercialize these medicines with the aim of improving the lives of patients. Vertex's commitment to innovation extends to collaborations with other organizations and efforts to advance science and health care for diseases with significant unmet needs.
What is VERX known for?
Snapshot
Public US
Ownership
1978
Year founded
2292
Employees
Pennsylvania, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Vertex
- Cystic Fibrosis Therapies: Revolutionized treatment of cystic fibrosis with a portfolio that targets the underlying cause of the disease, significantly improving patients' quality of life.
- Sickle Cell Disease and Beta Thalassemia Treatment: Developing gene-editing therapies aimed at treating these genetic disorders, potentially offering a cure or significant disease modification.
- Pain Management: An innovative approach to pain management intending to offer non-opioid, targeted treatments for acute and chronic pain, addressing a major medical need.
- Type 1 Diabetes: Engaged in research to create stem cell-derived therapies to potentially cure type 1 diabetes, aiming to replace the need for insulin injections.
- Alpha-1 Antitrypsin Deficiency (AATD): Working on treatments for AATD, a genetic disorder that can lead to significant lung disease, with the goal of addressing the root cause.
- APOL1-Mediated Kidney Disease: Focused on discovering and developing treatments for kidney diseases associated with APOL1 mutations, aiming to halt or reverse disease progression.
Vertex executive team
- Ms. Amanda Westphal RadcliffeCo-Owner & Independent Director
- Ms. Stefanie Westphal-Lucas ThompsonCo-Owner & Independent Director
- Mr. John R. SchwabChief Financial Officer
- Mr. Bryan T. R. RowlandSenior VP, General Counsel & Secretary
- Mr. Christopher David YoungCEO, President & Director
- Mr. Ray WestphalFounder
- Mr. Ryan J. Leib CPAChief Accounting Officer
- Mr. Salvatore ViscaChief Technology Officer
- Mr. Ben AskinChief Information Officer
- Mr. Joseph J. CrivelliVice President of Investor Relations